Dr. Kuykendall on Choosing Ruxolitinib or Fedratinib in Myelofibrosis


In Partnership With:

Andrew T. Kuykendall, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis.

Andrew T. Kuykendall, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of ruxolitinib (Jakafi) versus fedratinib (Inrebic) in patients with myelofibrosis.

Ruxolitinib is currently used in patients with intermediate- and high-risk disease as it has shown benefit in reducing disease-related symptoms and enlarged spleens. Although ruxolitinib has been shown to improve quality of life for patients, there is some debate regarding when to sequence the JAK1/JAK2 inhibitor.

In August 2019, fedratinib was approved in the same indication as ruxolitinib, Kuykendall says. Head-to-head comparison of the agents may provide insight into which patient populations will benefit more from one drug versus the other.

Notably, increased toxicity has been reported with fedratinib. These adverse events are mainly gastrointestinal in nature including nausea and diarrhea, Kuykendall concludes.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD